Aardvark Therapeutics, a clinical‑stage biopharma focused on metabolic diseases, is now the subject of a securities class action lawsuit following setbacks in its Phase 3 HERO trial of lead candidate ARD‑101.
The Peptide Connection
While ARD‑101 is a small‑molecule agonist of bitter taste receptors (TAS2Rs), its mechanism is designed to trigger secretion of endogenous signaling peptides such as cholecystokinin (CCK) and GLP‑1. These peptides play critical roles in satiety and hunger regulation, making them central to Aardvark’s positioning of ARD‑101 as a therapy for Prader‑Willi Syndrome (PWS), a rare disorder characterized by insatiable hunger.
Clinical Setbacks
The company voluntarily paused the HERO trial in February 2026 after “reversible cardiac observations” were detected at higher doses in a safety study. By May, the FDA imposed a full clinical hold on ARD‑101, halting all ongoing studies. Aardvark’s stock price fell sharply, dropping more than 56% in March and another 32% in May, leaving shares well below the $16 IPO price.
Legal Fallout
The lawsuit alleges that Aardvark’s IPO documents and subsequent public statements overstated the safety and prospects of ARD‑101, misleading investors. Plaintiffs claim the company failed to disclose material risks, including the potential for adverse cardiac effects.
The Bigger Picture
For the peptide industry, the case is a reminder of how peptide‑linked pathways like GLP‑1 and CCK are increasingly being leveraged by small‑molecule drugs. Even though ARD‑101 itself is not a peptide, its reliance on peptide signaling ties it to the broader metabolic drug ecosystem. The litigation underscores the risks companies face when translating peptide biology into commercial therapies, especially in high‑stakes indications like PWS.
Related Coverage: Peptide innovation is also reshaping beauty‑from‑within. See our coverage of Blue Cell Elixir’s collagen peptide micro‑dosing, which shows how smarter delivery can outperform traditional high‑dose collagen powders.